使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to the Lisata Therapeutics's third-quarter 2025 financial results and business update conference call.
歡迎參加 Lisata Therapeutics 2025 年第三季財務業績與業務更新電話會議。
(Operator Instructions) As a reminder, this call is being recorded today, Thursday, November 6, 2025.
(接線員指示)提醒您,本次電話會議將於今天(2025 年 11 月 6 日,星期四)錄音。
I will now turn the call over to John Menditto, Vice President of Investor Relations & Corporate Communications at Lisata. Please go ahead, sir.
現在我將把電話交給 Lisata 投資人關係與企業傳播副總裁 John Menditto。先生,請開始。
John Menditto - Vice President - Investor Relations & Corporate Communications
John Menditto - Vice President - Investor Relations & Corporate Communications
Thank you, operator. Good afternoon, everyone.
謝謝,接線員。各位下午好。
Welcome to Lisata's third-quarter 2025 conference call to discuss our financial results and to provide a business update.
歡迎參加 Lisata 2025 年第三季電話會議,我們將討論財務結果並提供業務更新。
Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research & Development and Chief Medical Officer; and James Nisco, Senior Vice President of Finance and Treasury and Chief Accounting Officer.
今天與我一同出席的管理團隊成員包括:總裁兼執行長 David Mazzo 醫師;研發執行副總裁兼首席醫療長 Kristen Buck 醫師;以及財務與資金管理資深副總裁兼首席會計長 James Nisco。
Shortly before this call, we issued a press release announcing our third-quarter 2025 financial results, which is available under the Investors & News section of the company website, along with a webcast replay of this call.
在本次電話會議開始前不久,我們已發布新聞稿,公布 2025 年第三季財務結果。新聞稿可於公司網站「Investors & News」專區取得,並可在該處收看本次電話會議的網路重播。
If you have not received the news release or if you'd like to be added to the company's e-mail distribution list, please subscribe to the e-mail alerts on the company website or e-mail me at jmenditto@lisata.com to be added.
若您尚未收到新聞稿,或希望加入公司電子郵件寄送名單,請於公司網站訂閱電子郵件提醒,或寄信至 jmenditto@lisata.com 與我聯繫以加入名單。
Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lisata.
在開始之前,提醒各位,管理層在本次電話會議中的評論將包含前瞻性陳述,涉及 Lisata 營運與未來業績之風險與不確定性。
I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its Forms 10-Q, 8-K, and 10-K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
建議您查閱公司向美國證券交易委員會(SEC)提交的文件,包括但不限於 10-Q、8-K 與 10-K 表格;其中列示可能導致實際結果或事件與前瞻性陳述所述內容出現重大差異的特定風險因素。
Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, November 6, 2025. Lisata Therapeutics undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.
此外,本次電話會議內容包含具時效性的資訊,僅截至本次直播日期(2025 年 11 月 6 日,星期四)為準。Lisata Therapeutics 不承擔在本次電話會議日期之後,因事件或情況變化而修訂或更新任何陳述之義務。
With that, I will now turn the call over to Dr. David Mazzo. Dave?
接下來,我將把電話交給 David Mazzo 醫師。Dave?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Thank you, John. Good afternoon, everyone.
謝謝你,John。各位下午好。
It's my pleasure to provide the latest update of Lisata's recent business highlights, discuss our third-quarter 2025 financial results, and give a report on the progress of our development programs.
我很高興向各位提供 Lisata 近期業務亮點的最新進展,討論 2025 年第三季財務結果,並報告我們開發計畫的進度。
Building on the momentum from the first half of the year, Lisata achieved several development milestones involving certepetide, including the announcement of encouraging preliminary results from multiple studies, including the ASCEND trial, the iLSTA trial, and the CENDIFOX trial, adding further corroboration to our expectations of the positive impact of certepetide as part of various anticancer treatment regimens.
在上半年動能的基礎上,Lisata 於 certepetide 方面達成多項開發里程碑,包括公布多項研究(含 ASCEND 試驗、iLSTA 試驗與 CENDIFOX 試驗)的令人鼓舞之初步結果,進一步佐證我們對 certepetide 作為多種抗癌治療方案一部分所能帶來正面影響的預期。
On the business development front, we entered into a strategic alliance with GATC Health to use their Multiomics Advanced Technology artificial intelligence drug discovery platform to identify product candidates for development.
在業務開發方面,我們與 GATC Health 建立策略聯盟,使用其 Multiomics Advanced Technology 人工智慧藥物發現平台,以辨識可供開發的產品候選物。
We also executed a non-exclusive global license agreement with Catalent in which Catalent gains access to certepetide and its analogs for use as a payload for their SMARTag ADC technology platform.
我們亦與 Catalent 簽署非專屬全球授權協議,Catalent 得以取得 certepetide 及其類似物,作為其 SMARTag ADC 技術平台的載荷(payload)使用。
We continue to anticipate that the next several quarters will be a data and transaction-rich period for Lisata, with several key milestones on the horizon.
我們仍預期未來數個季度將是 Lisata 數據與交易密集的期間,且有多項關鍵里程碑即將到來。
Following the review of our financial results, Dr. Kristen Buck, our Chief Medical Officer and Head of R&D, will provide an update on our ongoing and planned clinical studies, including timelines and key achievements.
在財務結果回顧之後,我們的首席醫療長暨研發主管 Kristen Buck 醫師將就我們正在進行及規劃中的臨床研究提供更新,包括時程與關鍵成果。
With that, I will now turn the call over to James Nisco, our Senior Vice President of Finance and Treasury and Chief Accounting Officer. James?
接下來,我將把電話交給我們的財務與資金管理資深副總裁兼首席會計長 James Nisco。James?
James Nisco - Senior Vice President - Finance and Treasury, Chief Accounting Officer
James Nisco - Senior Vice President - Finance and Treasury, Chief Accounting Officer
Thanks, Dave. Good afternoon, all.
謝謝,Dave。各位下午好。
I'm pleased to join you today to present a summary of our third-quarter 2025 financial results.
我很高興今天與各位一同回顧並摘要我們 2025 年第三季的財務結果。
Next, a review of our operating expenses. For the three months ended September 30, 2025, operating expenses totaled $4.4 million compared to $5.3 million for the three months ended September 30, 2024, representing a decrease of $0.9 million or 17.3%.
接著回顧營運費用。截至 2025 年 9 月 30 日止三個月,營運費用合計為 440 萬美元,較截至 2024 年 9 月 30 日止三個月的 530 萬美元減少 90 萬美元,降幅為 17.3%。
Research and development expenses were approximately $2 million for the three months ended September 30, 2025, compared to $2.5 million for the three months ended September 30, 2024, representing a decrease of $0.6 million or 22.9%. This was primarily due to lower spend on chemistry, manufacturing and controls, and a reduction in clinical department expenses, partially offset by an increase in the BOLSTER trial costs as a result of a CRO refund in the prior year quarter related to trial protocol modifications. On a year-over-year comparison for the nine months ended September 30, 2025, BOLSTER trial costs are lower than prior year.
截至 2025 年 9 月 30 日止三個月,研發費用約為 200 萬美元,較截至 2024 年 9 月 30 日止三個月的 250 萬美元減少 60 萬美元,降幅為 22.9%。主要原因為化學、製造與管制(CMC)支出較低,以及臨床部門費用下降;部分被 BOLSTER 試驗成本上升所抵銷,該上升係因前一年度同季曾就試驗方案修改相關事項收到 CRO 退款所致。以截至 2025 年 9 月 30 日止九個月的年對年比較而言,BOLSTER 試驗成本低於前一年。
General and administrative expenses were approximately $2.5 million for the three months ended September 30, 2025, compared to $2.8 million for the three months ended September 30, 2024, representing a decrease of $0.3 million or 12.1%. This was primarily due to lower spend on consulting and savings from the elimination of an employee position.
截至 2025 年 9 月 30 日止三個月,一般及行政費用約為 250 萬美元,較截至 2024 年 9 月 30 日止三個月的 280 萬美元減少 30 萬美元,降幅為 12.1%。主要原因為顧問支出降低,以及因取消一個員工職位而節省成本。
Overall, net losses were $4.2 million for the three months ended September 30, 2025, compared to $4.9 million for the three months ended September 30, 2024.
整體而言,截至 2025 年 9 月 30 日止三個月的淨損為 420 萬美元,較截至 2024 年 9 月 30 日止三個月的 490 萬美元為低。
It is noteworthy that we continue to make progress according to our plans for our R&D and business activities, while continuing our legacy of prudent capital management and expense minimization.
值得注意的是,我們在推進研發與業務活動計畫的同時,仍延續審慎的資本管理與費用最小化的傳統。
Turning now to our balance sheet and cash flow, as of September 30, 2025, we had cash and cash equivalents of approximately $19 million.
接著看資產負債表與現金流量,截至 2025 年 9 月 30 日,我們持有的現金及約當現金約為 1,900 萬美元。
Based on our existing and planned activities, the company projects that available funds will support current operations into the first quarter of 2027.
基於現有及規劃中的活動,公司預估可用資金將可支持目前營運至 2027 年第一季。
With that, I will now turn the call over to Dr. Kristen Buck to provide an overview of the company's development programs. Kristen?
接下來,我將把電話交給 Kristen Buck 醫師,請她概述公司的開發計畫。Kristen?
Kristen Buck - Executive Vice President - Research & Development, Chief Medical Officer
Kristen Buck - Executive Vice President - Research & Development, Chief Medical Officer
Thank you, James. Good afternoon, everyone.
謝謝你,James。各位下午好。
It's a pleasure to be here today to present an update on our clinical development portfolio, including near-term catalysts.
我很高興今天在此就我們的臨床開發產品組合提供更新,包括近期的催化劑(near-term catalysts)。
As mentioned on previous quarterly calls, Lisata is focused on the development of its proprietary cyclic internalizing RGD peptide product candidate, certepetide, for the treatment of advanced solid tumors and other difficult-to-treat diseases.
如同先前季度電話會議所提及,Lisata 專注於開發其專有的環狀內化 RGD 胜肽產品候選物 certepetide,用於治療晚期實體腫瘤及其他難以治療的疾病。
Certepetide is designed to activate a novel uptake pathway that allows co-administered or tethered anticancer drugs to selectively target and penetrate solid tumors more effectively. In addition, certepetide has been shown to modify the tumor microenvironment, making it less immunosuppressive and, therefore, increasing the tumor's susceptibility to immunotherapy and our body's own immune system, while also inhibiting the metastatic cascade.
Certepetide 的設計旨在啟動一條新型攝取途徑,使共同給藥或以繫鏈方式連接的抗癌藥物能更具選擇性地靶向並更有效地穿透實體腫瘤。此外,certepetide 已被證實可改變腫瘤微環境,使其免疫抑制性降低,因而提高腫瘤對免疫治療及人體自身免疫系統的敏感性,同時也抑制轉移級聯反應。
If you'd like more information regarding certepetide's mechanism of action, we encourage you to visit our website where you'll find an animated video and relevant slides within our corporate presentation.
若您希望進一步了解 certepetide 的作用機制,我們建議您造訪公司網站;您可在其中找到動畫影片,以及公司簡報中的相關投影片。
On the regulatory front, certepetide has secured multiple special designations from both the US FDA and EMA, all of which are also listed on our website and in the corporate presentation for your easy reference.
在法規監管方面,certepetide 已獲得美國 FDA 與 EMA 授予的多項特殊認定;相關內容亦已列於我們的網站及公司簡報中,便於您查閱。
Now, for an update on our individual development programs. The ASCEND trial is a Phase 2b 158-patient double-blind, randomized, placebo-controlled clinical trial evaluating certepetide in combination with standard of care gemcitabine and nab-paclitaxel chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma, or mPDAC.
現在,更新我們各項個別開發計畫。ASCEND 試驗為一項第 2b 期、158 名受試者的雙盲、隨機、安慰劑對照臨床試驗,評估 certepetide 與標準治療(gemcitabine 與 nab-paclitaxel 化療)併用,用於轉移性胰臟導管腺癌(metastatic pancreatic ductal adenocarcinoma,或 mPDAC)患者。
Patient recruitment was conducted at 25 sites in Australia and New Zealand and is sponsored by the Australasian Gastro-Intestinal Clinical Trials Group, or AGITG, in collaboration with the National Health and Medical Research Council Clinical Trials Center at the University of Sydney.
受試者招募於澳洲與紐西蘭的 25 個試驗中心進行,並由澳大拉西亞胃腸道臨床試驗組(Australasian Gastro-Intestinal Clinical Trials Group,或 AGITG)主辦,並與雪梨大學之國家健康與醫學研究委員會臨床試驗中心合作。
As we mentioned in the past, this investigator-initiated trial was inherited upon our acquisition of Cend Therapeutics. The original trial was designed with an academic bent, rather than one with the commercial and regulatory objectives; and was statistically powered based on a six-month progression-free survival primary endpoint. This endpoint is unusual in that it has not been previously used as the basis of approval for an anticancer drug.
如我們過去所提及,這項由研究者發起的試驗是在我們收購 Cend Therapeutics 時一併承接。原始試驗設計較偏學術取向,而非以商業與法規目標為導向;其統計檢定力係以「六個月無惡化存活期」作為主要終點而設定。此終點較為罕見,因其過去未曾作為抗癌藥物核准的依據。
After the acquisition, Lisata collaborated with the AGITG to modify the trial to ensure it measured clinical endpoints that would best support the next steps in development of certepetide from a regulatory perspective.
收購完成後,Lisata 與 AGITG 合作修改試驗,以確保其衡量之臨床終點能從法規角度最佳支持 certepetide 後續開發步驟。
To that end, the ASCEND protocol was amended to include another cohort of patients, Cohort B, not statistically powered, to evaluate an additional certepetide dosing regimen. The ASCEND protocol was also amended to capture overall survival outcomes for both Cohorts A and B as overall survival is considered by regulatory authorities to be the gold standard endpoint in pancreatic cancer trials.
為此,ASCEND 方案修訂新增另一組受試者隊列(Cohort B),該隊列未設定統計檢定力,用以評估另一種 certepetide 給藥方案。ASCEND 方案亦修訂以蒐集 A 與 B 兩個隊列的整體存活(overall survival)結果,因整體存活被監管機關視為胰臟癌試驗的黃金標準終點。
Since the ASCEND protocol was amended following trial initiation, data from Cohort B are being analyzed sequentially, following Cohort A data. Cohort A, with 95 patients receiving a single intravenous dose of certepetide or placebo, in combination with standard of care, completed enrollment in the third quarter of 2023.
由於 ASCEND 方案是在試驗啟動後才修訂,Cohort B 的資料將在 Cohort A 資料之後依序分析。Cohort A 共 95 名受試者,接受單次靜脈注射 certepetide 或安慰劑,並與標準治療併用,已於 2023 年第三季完成收案。
As announced in January of this year, preliminary Cohort A data was presented at the 2025 ASCO GI Symposium, which showed a positive trend in overall survival in the certepetide plus standard of care chemotherapy group, including four complete responses in this group compared to none in the standard of care plus placebo-treated group.
如今年 1 月所公告,Cohort A 的初步資料已於 2025 年 ASCO GI Symposium 發表,顯示在「certepetide 加上標準治療化療」組的整體存活呈現正向趨勢;且該組出現 4 例完全緩解(complete response),相較之下,「標準治療加安慰劑」組則無。
Most recently, preliminary data from Cohort B, with 63 patients receiving two intravenous doses of certepetide, 3.2 milligram per kilogram or placebo, administered four hours apart, in combination with standard-of-care chemotherapy, were presented at the ESMO Gastrointestinal Cancers Congress on July 2, 2025.
最近,Cohort B 的初步資料於 2025 年 7 月 2 日在 ESMO Gastrointestinal Cancers Congress 發表;該隊列共 63 名受試者,接受兩次靜脈注射 certepetide(3.2 毫克/公斤)或安慰劑,兩次給藥間隔四小時,並與標準治療化療併用。
These data showed a positive trend in progression-free survival, overall survival, and objective response rate in the certepetide plus standard-of-care treatment group compared to the standard of care plus placebo treated group.
這些資料顯示,相較於「標準治療加安慰劑」組,「certepetide 加標準治療」組在無惡化存活期(progression-free survival)、整體存活(overall survival)以及客觀反應率(objective response rate)方面均呈現正向趨勢。
Another complete response was also noted in the certepetide plus standard of care treated group, while none were observed in the standard of care plus placebo group.
此外,在「certepetide 加標準治療」組亦觀察到另一例完全緩解,而「標準治療加安慰劑」組則未觀察到。
Additionally, full data from both Cohorts A and B, which was presented at the ESMO Congress in October 2025, further corroborated previous findings and indicated no increase in adverse events in the certepetide plus standard of care treated group beyond those experienced in the standard of care plus placebo-treated groups.
另外,於 2025 年 10 月 ESMO Congress 發表之 A 與 B 兩個隊列的完整資料,進一步佐證先前發現,並顯示「certepetide 加標準治療」組的不良事件並未較「標準治療加安慰劑」組所經歷者增加。
Final data and conclusions from both cohorts are anticipated for the first quarter of 2026.
預期將於 2026 年第一季取得兩個隊列的最終資料與結論。
As we have previously announced, we have completed an end of Phase 2 meeting with the FDA and, in conjunction with other correspondence with the agency, have an agreement on the fundamental aspects of an acceptable global Phase 3 protocol, including dose and dosing regimen, blinding, and primary endpoints.
如先前所公告,我們已與 FDA 完成第 2 期結束(end of Phase 2)會議,並結合與該機關的其他往來函件,就可接受的全球第 3 期方案之基本要素達成一致,包括劑量與給藥方案、盲法設計以及主要終點。
Subsequently, we have begun preparation for Phase 3 trial initiation, as contingent upon available capital and anticipated capital acquisition.
其後,我們已開始為第 3 期試驗啟動做準備,惟仍取決於可用資金以及預期的資金取得情況。
The BOLSTER trial is our Phase 2a double-blind, placebo-controlled, multicenter randomized trial in the United States, evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy in first- and second-line cholangiocarcinoma, on top of standard of care.
BOLSTER 試驗為我們在美國進行的第 2a 期、雙盲、安慰劑對照、多中心隨機試驗,評估 certepetide 與標準治療化療及免疫治療併用,用於第一線與第二線膽管癌(cholangiocarcinoma),並在標準治療基礎上加用。
Enrollment was completed in the first-line cholangiocarcinoma arm nearly six months ahead of plan, accelerating anticipated top line data readout to the fourth quarter of 2025. Based on encouragement from multiple investigators involved in the trial, a second cohort was added, evaluating certepetide in subjects in second-line cholangiocarcinoma. Although originally planned to recruit 40 patients, enrollment was ultimately capped at approximately 20 patients to allow for quicker data analysis and a more efficient use of our capital.
第一線膽管癌組別的收案已較原計畫提前近六個月完成,使預期的主要(top line)數據讀出加速至 2025 年第四季。基於多位參與試驗之研究者的鼓勵,新增第二個隊列以評估 certepetide 用於第二線膽管癌受試者。雖原先規劃招募 40 名患者,但最終將收案上限設定為約 20 名,以利更快速的資料分析並更有效率地運用資金。
It should be noted that this exploratory trial is not statistically powered. However, the reduced number of patients in the second-line arm should be sufficient to determine if there is a treatment effect.
需注意的是,此探索性試驗未設定統計檢定力。然而,第二線組別的受試者數量雖減少,仍應足以判斷是否存在治療效果。
The CENDIFOX trial is a Phase 1b/2a open-label trial in the United States evaluating certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon, and appendiceal cancers.
CENDIFOX 試驗為一項在美國進行的第 1b/2a 期開放標籤試驗,評估 certepetide 與術前輔助(neoadjuvant)FOLFIRINOX 為基礎之治療併用,用於胰臟癌、結腸癌與闌尾癌。
In December 2024, the company announced enrollment completion in all three cohorts. This single-center study being conducted at the University of Kansas Cancer Center was designed with a three-cycle run-in period to ensure patients met specific criteria before receiving treatment.
公司於 2024 年 12 月宣布三個隊列皆已完成收案。此單中心研究於堪薩斯大學癌症中心進行,設計包含三個療程的導入期(run-in period),以確保患者在接受治療前符合特定條件。
Of the 66 patients enrolled, 50 met these criteria and were treated with certepetide across three cohorts, including 24 with resectable or borderline resectable pancreatic cancer, 15 with high-grade colon or appendiceal cancers with peritoneal metastases, and 11 with oligometastatic colon cancer.
在收案的 66 名患者中,有 50 名符合條件並於三個隊列接受 certepetide 治療,包括 24 名可切除或邊界可切除胰臟癌、15 名伴腹膜轉移的高惡性度結腸或闌尾癌,以及 11 名寡轉移(oligometastatic)結腸癌。
Preliminary data from the pancreatic cancer cohort presented at the AACR Special Conference in September of '25 showed that the combination of certepetide with FOLFIRINOX was safe and feasible. In the 10 patients who completed the therapy and underwent surgery, treatment resulted in a 50% R0 resection rate and a 70% pathological partial response, alongside promising early survival data, including a 60% two-year overall survival rate.
於 2025 年 9 月 AACR Special Conference 發表的胰臟癌隊列初步資料顯示,certepetide 與 FOLFIRINOX 的合併治療安全且可行。在完成治療並接受手術的 10 名患者中,治療達到 50% 的 R0 切除率與 70% 的病理部分反應(pathological partial response),並伴隨具前景的早期存活資料,包括 60% 的兩年整體存活率。
Importantly, the combination therapy appears to transform tumors from immuno-cold to immuno-hot by enhancing immune cell infiltration and increasing markers like PD-1 and PD-L1, which could significantly improve the effect of subsequent immunotherapies.
重要的是,該合併療法似乎可透過增強免疫細胞浸潤並提高如 PD-1 與 PD-L1 等標記,將腫瘤由免疫冷(immuno-cold)轉變為免疫熱(immuno-hot),這可能顯著提升後續免疫治療的效果。
Additional data from the CENDIFOX trial are anticipated in the coming months. The trial is funded by the University of Kansas Cancer Center and Lisata is supplying certepetide.
CENDIFOX 試驗的更多資料預期將於未來數月公布。該試驗由堪薩斯大學癌症中心資助,Lisata 提供 certepetide。
Qilu Pharmaceutical, the licensee of certepetide in the Greater China territory, is running a parallel development program for certepetide in combination with gemcitabine and nab-paclitaxel as a treatment for metastatic pancreatic cancer.
齊魯製藥(Qilu Pharmaceutical)為 certepetide 在大中華區的被授權方,正進行一項平行開發計畫,評估 certepetide 與 gemcitabine 及 nab-paclitaxel 併用,作為轉移性胰臟癌的治療。
Qilu previously reported that they completed enrollment in the study of 96 subjects. However, we still await data from the study to be shared. Also, according to guidance last received from Qilu, data are expected in the next 12 to 18 months. We anticipate ongoing dialogue to continue related to potential next steps in the development plan.
齊魯先前回報其已完成 96 名受試者之研究收案。然而,我們仍在等待該研究資料分享。此外,依據我們最近一次自齊魯取得的指引,預期資料將於未來 12 至 18 個月內取得。我們預期將持續就開發計畫可能的後續步驟進行對話。
The iLSTA trial is a Phase 1b/2a randomized, placebo-controlled, three-arm, single-blind, single-center trial evaluating the safety, early efficacy, and pharmacodynamics of certepetide in patients with locally advanced non-resectable pancreatic cancer. The trial is being conducted in Australia in collaboration with AstraZeneca and the funding sponsor WARPNINE, combining certepetide with a checkpoint inhibitor, durvalumab, with standard-of-care gemcitabine and nab-paclitaxel chemotherapy versus certepetide in combination with standard-of-care chemotherapy without durvalumab versus standard of care alone.
iLSTA 試驗為第 1b/2a 期隨機、安慰劑對照、三組、單盲、單中心試驗,評估 certepetide 用於局部晚期不可切除胰臟癌患者之安全性、早期療效與藥效動力學。該試驗於澳洲進行,並與阿斯特捷利康(AstraZeneca)及資助方 WARPNINE 合作,將 certepetide 與免疫檢查點抑制劑 durvalumab 併用標準治療之 gemcitabine 與 nab-paclitaxel 化療,對照為 certepetide 併用標準治療化療但不含 durvalumab,以及僅採標準治療。
As recently announced, enrollment in the iLSTA study is complete. An updated interim analysis presented at ESMO GI Congress on July 3, 2025, revealed compelling positive preliminary data for certepetide.
如近期所公布,iLSTA 研究已完成收案。於 2025 年 7 月 3 日 ESMO GI 大會發表的更新期中分析,揭示了對 certepetide 具說服力的正向初步數據。
These data are consistent with earlier findings from the 2025 ASCO GI meeting, further reinforcing certepetide's potential to significantly enhance immunotherapy effectiveness by provoking significant RECIST responses, improving overall response, and disease control rates. Final data and key findings from this study are anticipated in the first quarter of 2026.
這些數據與 2025 年 ASCO GI 會議的早期發現一致,進一步強化 certepetide 透過引發顯著的 RECIST 反應、提升整體反應率與疾病控制率,而有望大幅增強免疫治療效果的潛力。預計將於 2026 年第一季公布本研究的最終數據與關鍵發現。
A study of certepetide in combination with temozolomide in patients with glioblastoma multiforme, or GBM, brain cancer has been initiated with many patients already enrolled and treated. This study is designed as a Phase 2a, double-blind, placebo-controlled, randomized proof-of-concept study evaluating certepetide when added to standard-of-care temozolomide versus temozolomide alone and matching certepetide placebo in subjects with newly diagnosed GBM.
certepetide 與 temozolomide 併用於多形性膠質母細胞瘤(glioblastoma multiforme,GBM)腦癌患者的研究已啟動,且已有多名患者完成收案並接受治療。本研究設計為第 2a 期、雙盲、安慰劑對照、隨機之概念驗證研究,評估在新診斷 GBM 受試者中,於標準治療 temozolomide 基礎上加用 certepetide,相較於僅用 temozolomide 並搭配相符的 certepetide 安慰劑。
This actively enrolling study is being conducted across multiple sites in Estonia, Latvia, and Lithuania. The study is targeted to enroll 30 patients with a randomization of 2:1 certepetide plus standard of care versus placebo plus standard of care. Enrollment is progressing according to plan and completion of enrollment is expected in 2026.
此項積極收案中的研究於愛沙尼亞、拉脫維亞與立陶宛多個據點進行。研究目標收案 30 名患者,並以 2:1 隨機分派至「certepetide 加標準治療」對「安慰劑加標準治療」。收案進度依計畫推進,預期將於 2026 年完成收案。
As a reminder, several of the clinical trials I mentioned are investigator-initiated trials; meaning, Lisata has limited control over study timelines and expectations may be subject to change. That said, we are incredibly grateful to the investigators and especially to the patients participating in certepetide clinical trials around the world.
提醒一下,我提到的數項臨床試驗屬研究者發起試驗(investigator-initiated trials);也就是說,Lisata 對研究時程的掌控有限,相關預期可能有所變動。即便如此,我們仍非常感謝研究者,尤其是全球參與 certepetide 臨床試驗的患者。
For more information on each trial, please refer to the Appendix section of our corporate presentation on our website. The presentation also includes two slides illustrating the anticipated timelines and execution of key milestones and data readouts.
如需各試驗的更多資訊,請參閱我們網站上公司簡報的附錄(Appendix)章節。該簡報亦包含兩張投影片,說明預期時程、關鍵里程碑的執行,以及數據讀出(data readouts)。
Moving on to exciting business development achievements, as Dave mentioned earlier, Lisata and Catalent entered in a non-exclusive license agreement that grants Catalent global rights to evaluate certepetide and its analogs for use as SMARTag payloads across multiple antibody drug conjugates or ADCs designed to address difficult diseases, including advanced solid tumors.
接著談令人振奮的業務開發成果,如 Dave 先前所述,Lisata 與 Catalent 簽訂非獨家授權協議,授予 Catalent 全球權利,可評估 certepetide 及其類似物作為 SMARTag 載荷(payload),用於多種抗體藥物複合體(antibody drug conjugates,ADC),以因應包含晚期實體腫瘤在內的棘手疾病。
As presented at the World ADC Conference earlier this week, compelling positive data from Catalent's preclinical study showed both improved tumor selective penetration and enhanced efficacy, further highlighting certepetide's strong potential to significantly improve the targeting and overall effectiveness of ADCs in advanced solid tumors.
如本週稍早於 World ADC Conference 所展示,Catalent 的臨床前研究取得具說服力的正向數據,顯示腫瘤選擇性滲透提升且療效增強,進一步凸顯 certepetide 在晚期實體腫瘤中,顯著改善 ADC 靶向性與整體效力的強大潛力。
Additionally, we've established a strategic alliance with GATC Health. This partnership combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology platform to accelerate and optimize drug discovery.
此外,我們已與 GATC Health 建立策略聯盟。此合作結合 Lisata 的藥物開發專長與 GATC 以 AI 驅動的 Multiomics Advanced Technology 平台,以加速並最佳化藥物發現。
This includes in silico assessment of certepetide for new indications, including some outside of oncology; as well as identifying new chemical entities and/or repurposed existing drugs for diseases with high unmet needs, including non-oncology applications with and without certepetide.
合作內容包括以 in silico 方式評估 certepetide 的新適應症(包含部分腫瘤學以外領域);以及針對高度未被滿足醫療需求的疾病,辨識新的化學實體(new chemical entities)和/或重新定位既有藥物,用於包含有無 certepetide 之非腫瘤學應用。
The alliance has already identified a number of development candidates, several of which are anticipated to translate into clinical development during 2026.
該聯盟已辨識出多項開發候選項目,其中數項預期將於 2026 年推進至臨床開發。
Further strengthening our intellectual property portfolio, the United States Patent and Trademark Office issued a new composition of matter patent for certepetide in July 2025, extending our protection until March 2040, with the potential for further extensions. The patent claim covers certepetide's chemical structures, pharmacokinetic properties, methods of manufacturing, and applications for treating solid tumors.
為進一步強化我們的智慧財產權組合,美國專利商標局(USPTO)於 2025 年 7 月核發 certepetide 的新物質組成(composition of matter)專利,將保護期延長至 2040 年 3 月,且仍有進一步延展的可能。該專利權利要求涵蓋 certepetide 的化學結構、藥物動力學特性、製造方法,以及用於治療實體腫瘤的應用。
With that, I will now turn the call back to Dave.
接下來我把電話交回給 Dave。
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Thanks, Kristen.
謝謝你,Kristen。
In summary, the past quarter has been active and fruitful, as we have both advanced the broad development of certepetide while identifying means by which to expand and diversify Lisata's development pipeline.
總結而言,過去一季相當活躍且成果豐碩;我們一方面推進 certepetide 的廣泛開發,同時也找出可擴大並多元化 Lisata 開發管線的方法。
We continue to evaluate opportunities to bring new products to patients across a variety of cancer and noncancer indications.
我們持續評估機會,將新產品帶給患者,涵蓋多種癌症與非癌症適應症。
I look forward to sharing our progress on future calls. With that overview, operator, we're now ready to take questions.
我期待在未來的電話會議中分享我們的進展。以上為概述,接線員,我們現在準備開始回答問題。
Operator
Operator
(Operator Instructions)
(接線員指示)
Joe Pantginis, H.C. Wainwright.
Joe Pantginis,H.C. Wainwright。
Lander Egaña-Gorroño - Analyst
Lander Egaña-Gorroño - Analyst
This is Lander, on for Joe.
我是 Lander,代 Joe 發言。
For CENDIFOX, when approximately should we expect the next Phase 2b data cut?
關於 CENDIFOX,我們大約何時可以預期下一次第 2b 期數據切點(data cut)?
For the GBM trial, could you provide some color on the enrollment status for the target sample size?
關於 GBM 試驗,能否就目標樣本數的收案狀況提供一些說明?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Lander, thanks for joining and for asking the questions.
Lander,謝謝你加入並提出問題。
On CENDIFOX, unfortunately, we really can't give a very precise estimate of when the next data cut will be made available because it's really under the control of the investigator at the University of Kansas Cancer Center.
就 CENDIFOX 而言,很遺憾我們無法非常精準地估計下一次數據切點何時可提供,因為這主要由堪薩斯大學癌症中心的研究者掌控。
So we'll stay close to him. We obviously encourage him to keep things moving along. But the academic world moves at a different pace than the commercial development world.
因此我們會與他保持密切聯繫。我們當然也鼓勵他持續推進。但學術界的節奏與商業開發領域不同。
And then, as it relates to -- what was your second question?
另外,關於——你的第二個問題是什麼?
Lander Egaña-Gorroño - Analyst
Lander Egaña-Gorroño - Analyst
The GBM trial enrollment status?
GBM 試驗的收案狀況?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
As it relates to GBM trial, as Kristen mentioned, we're completely on track with that. The target is to enroll 30 patients. I would say that we're approximately two-thirds of the way through. So things are moving very well according to plan.
就 GBM 試驗而言,如 Kristen 所提,我們完全依計畫進行。目標收案 30 名患者。我會說目前大約完成了三分之二。因此整體進展非常順利,符合計畫。
Operator
Operator
Robert Sassoon, Water Tower Research.
Robert Sassoon,Water Tower Research。
Robert Sassoon - Analyst
Robert Sassoon - Analyst
Just a couple of questions.
我有幾個問題。
Your cash flow runway to the first quarter of '27, what is that actually -- can you run through what that really includes, in terms of expenditures going into 2026?
你們的現金流可支撐到 2027 年第一季,這實際上——能否說明其中包含哪些項目,特別是 2026 年的支出假設?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Yeah. Sure. Thanks for the question.
好的,當然。謝謝你的提問。
James is on the line if we want to go into more detail. But, generally speaking, that covers all of the operating expenses for the company, as well as all the expenses to support the ongoing and complete the ongoing clinical trials.
如果要更深入的細節,James 也在線上。不過一般而言,這涵蓋公司所有營運費用,以及支持現行臨床試驗持續進行並完成所需的所有費用。
Robert Sassoon - Analyst
Robert Sassoon - Analyst
Is there any assumption of Phase 3 trial for ASCEND is actually incorporated into those assumptions?
這些假設中是否已納入 ASCEND 第 3 期試驗的假設?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
There is not.
沒有。
Robert Sassoon - Analyst
Robert Sassoon - Analyst
Okay. One more question for me.
好的。我還有一個問題。
You've come out with some pretty robust clinical data, a series of them over the past year. Your share price has not really reacted to it in the way that one would expect for that type of data.
你們在過去一年發布了一系列相當強勁的臨床數據。但你們的股價並未如人們對這類數據所預期的那樣有所反應。
What do you think the investors are missing?
你認為投資人忽略了什麼?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Everything, candidly. I think the problem is a confluence of negative forces that seem to be affecting lots of small-cap companies. But it's especially frustrating for Lisata, where, as you pointed out, we continue to generate positive results across a wide variety of studies. We continue to manage our capital extremely prudently. We continue to make very, I think, astute business deals; and yet, the stock doesn't react.
坦白說,是所有事情。我認為問題是多股負面力量的匯聚,似乎影響了許多小型股公司。但對 Lisata 來說尤其令人沮喪,因為如你所指出,我們持續在各式各樣的研究中產出正向結果。我們持續以極為審慎的方式管理資本。我們也持續達成我認為相當精明的商業交易;然而股價卻沒有反應。
I think that's partly because the macro environment is not favoring small-cap biotech these days. So there aren't quite a lot of buyers.
我認為這部分是因為目前的總體環境並不利於小型生技股。因此買方並不多。
We're also stuck in a difficult situation because many of our shareholders treat their holdings in Lisata as a venture capitalist might. In other words, they've made their purchases quite a while ago. They're holding for the long run. So they don't trade.
我們也陷入一個困難的處境,因為我們許多股東對 Lisata 的持股方式就像創投一樣。換言之,他們是在相當久以前買進的。他們是長期持有。所以他們不交易。
With a limited float like we have on a given day, a very small number of trades could make the market. That makes our stock somewhat volatile. So I think we are continuing to look for ways to break that paradigm. Our best efforts are to continue to do positive transactions and generate positive data.
在像我們這樣每日可流通股數有限的情況下,極少數的成交就可能形成市場價格。這使得我們的股票波動性偏高。因此我認為我們仍在持續尋找方法來打破這種典範。我們最好的努力就是持續完成正向的交易並產出正向的數據。
But in terms of what the market is missing, I think they're missing that there's quite a lot of value in a product that can be used. We've demonstrated now that it can be used very broadly across a number of different types of cancers in a variety of different combinations.
但就市場忽略了什麼而言,我認為他們忽略的是:一個可被實際使用的產品具有相當大的價值。我們現在已經證明,它可以非常廣泛地應用於多種不同癌症類型,並且可在各式不同的聯合療法中使用。
Operator
Operator
Pete Enderlin, MAZ Partners.
Pete Enderlin,MAZ Partners。
Peter Enderlin - Analyst
Peter Enderlin - Analyst
First, this biotech achievement award, breakthrough award, that you got overall -- is the word used -- does that mean that you're the only one that got that? There might be other lesser awards but is that basically the only number 1 award of that type given, at this time?
首先,這個你們獲得的生技成就獎、突破獎(用的就是這個詞)——這是否表示只有你們拿到?可能還有其他較小的獎項,但就目前而言,這基本上是此類型唯一的第一名獎項嗎?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
I think we can say that that's the only award with that title or name, yes, Pete.
我想我們可以說,是的,Pete,這是唯一使用該頭銜或名稱的獎項。
Peter Enderlin - Analyst
Peter Enderlin - Analyst
Okay. It seems so trivial but the reason I'm asking that is -- and Dave, you said before that potential licensees or partners want to see more clinical results. Also, of course, we've seen a lot of positive results recently but, as we all said, the stock hasn't responded.
好的。這看起來很瑣碎,但我之所以問是因為——而且 Dave,你之前說過潛在被授權方或合作夥伴想看到更多臨床結果。當然,我們最近也看到很多正向結果,但如同大家所說,股價並沒有反應。
Given the broad application of certepetide and maybe some other aspects, too, in immunotherapy and chemotherapy, the question that I'm really getting at is, wouldn't it make sense to take a broad-brush approach to potential licensees and make a push for that now that you're starting to gain some momentum and that you could use the ones that you've gotten, Catalent and the others, for referrals; and, therefore, beat the bushes for some additional licenses given that, for example, Catalent is a non-exclusive license, they would all be non-exclusive because each one would apply to a particular disease and a particular drug?
鑑於 certepetide 的廣泛應用,以及可能還有其他面向,涵蓋免疫治療與化療,我真正想問的是:既然你們開始累積一些動能,是否應該對潛在被授權方採取更廣泛的策略並現在就加大推進力道?而且你們可以利用已經拿到的 Catalent 以及其他合作作為引薦;因此,鑑於例如 Catalent 是非獨家授權,其他也都會是非獨家,因為每一個授權都會對應特定疾病與特定藥物——那麼是否應該積極去爭取更多授權?
I know you're probably going to say it costs money. But I have an idea to address that, too, which is what about using independent consultants on a contingency fee basis to go out and do that, beating the bushes to get licensees?
我知道你可能會說這需要花錢。但我也有一個想法可以解決:是否可以用獨立顧問採取成功酬金(按成果計費)的方式,讓他們出去做這件事,積極去尋找被授權方?
I know that's a lot but I just wanted to throw it all out there.
我知道這問題很長,但我只是想把想法都提出來。
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
I think you've done -- actually, in the form of a question, you've actually done a nice job of describing our actual ongoing strategy and execution. That's exactly what we're doing.
我認為你——其實你用提問的形式——很好地描述了我們目前正在進行的策略與執行方式。這正是我們在做的事。
We don't need to do that with external consultants. We do that with our internal staff who know the product extremely well. And so that's exactly what we're doing on a regular basis.
我們不需要外部顧問。我們由內部團隊來做,因為他們對產品非常了解。因此我們就是定期在做這件事。
We're building on the momentum of the previous non-exclusive licenses and the interest that was shown in those deals to generate new interest and, hopefully, build a greater consortium of different licensees.
我們正利用先前非獨家授權所帶來的動能,以及那些交易所展現的興趣,來產生新的興趣,並希望建立一個更大的、由不同被授權方組成的聯盟。
Peter Enderlin - Analyst
Peter Enderlin - Analyst
Okay. Great. Just following up on a previous question.
好的。很好。接著追問一個先前的問題。
The burn rate looks like it will be roughly $3 million per quarter for the next five quarters. Is it going to be fairly level over that period of time?
未來五個季度的資金消耗率看起來大約每季 300 萬美元。在那段期間會大致持平嗎?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Well, let me put it this way and listen carefully to the way I state this so I'm not misquoting anyone. But I hope not. I actually hope it's going to go up.
嗯,我這樣說,請仔細聽我表述的方式,避免誤引任何人的話。但我希望不是。我其實希望它會上升。
I want it to go up because I want us to be doing more studies, which will be generating more data, which is how a company like Lisata ultimately generates values for shareholders.
我希望它上升,因為我希望我們能做更多研究,產出更多數據,而這正是像 Lisata 這樣的公司最終為股東創造價值的方式。
Now, of course, to do that, we'll likely have to raise some capital to supplement our current balance sheet. But that would be the plan.
當然,要做到這點,我們很可能需要募資,以補強目前的資產負債表。但這會是計畫。
Now, there are ways for capital to come in through licensing fees, et cetera, that are non-dilutive. Of course, we'll give those priority.
另外,也有一些資金可以透過授權費等方式進來,屬於非稀釋性資金。當然,我們會優先考慮這些。
Operator
Operator
Kemp Dolliver, Brookline Capital Markets.
Kemp Dolliver,Brookline Capital Markets。
Brian Kemp Dolliver - Analyst
Brian Kemp Dolliver - Analyst
With the final analysis of the ASCEND data coming relatively soon, could you talk about your thinking for the next steps because as everybody on this call knows, you need to raise a substantial amount of money to fund the Phase 3? There's some orchestration that goes on to get that done. And so I'd like to know you're thinking about the steps in the process you'll lay out to do so.
ASCEND 數據的最終分析相對很快就會出來,你能談談你們對下一步的想法嗎?因為本次電話會議上的每個人都知道,你們需要募集一大筆資金來支應第三期試驗。要完成這件事需要一些協調安排。因此我想了解你們對流程中各步驟的思考與規劃。
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Thanks, Kemp, for the question and, actually, the opportunity to be clear on what our plans are.
謝謝你,Kemp,這個問題也讓我們有機會清楚說明我們的計畫。
Based upon the data that's been generated from the Phase 2b trial, we've concluded, internally, that the drug deserves further development and that moving to Phase 3 would be the logical next step.
根據第二期 b 試驗所產生的數據,我們在內部已得出結論:這個藥物值得進一步開發,而推進到第三期將是合乎邏輯的下一步。
Clearly, in this current financing environment, it's going to be next to impossible to raise the amount of money necessary to unilaterally fund that Phase 3 in a manner that would not be so overly dilutive to current shareholders as to be distasteful.
很明顯,在目前的融資環境下,要募集到足以單方面資助第三期試驗所需的金額幾乎是不可能的;而且若以不致對現有股東造成過度稀釋的方式來做,更會令人難以接受。
So we are working, much to Pete's suggestion, the previous questioner -- working to find licensees and partners who will be willing to bear the brunt of that funding or at least contribute in an equal manner to that funding so that we can get that trial done.
因此,我們正如 Pete 的建議、也就是前一位提問者所說——努力尋找願意承擔主要資金需求的被授權方與合作夥伴,或至少願意以對等方式共同出資,讓我們能完成該試驗。
In the meantime, we've done everything we can and continue to do everything we can, internally, with existing resources to be prepared to move into Phase 3, including completing activities on the CMC side that would have us poised for Phase 3 production and NDA validation-lot production; having the end of Phase 2b meeting with FDA to discuss and agree on a protocol; and preparing similar discussions with other regulatory agencies around the world, looking for some consensus on a global protocol; beginning to have early dialogue with CROs that might be involved in certain areas; and, of course, looking for partners and means to fund that trial.
同時,我們已經盡一切所能,並持續在內部以現有資源做好進入第三期的準備,包括:完成 CMC 端的相關工作,使我們能為第三期生產以及 NDA 驗證批次(validation-lot)生產做好就緒;與 FDA 進行第二期 b 結束會議(End-of-Phase 2b meeting)以討論並同意試驗方案;並準備與全球其他監管機構進行類似討論,尋求全球試驗方案的共識;開始與可能在特定區域參與的 CRO 進行早期對話;當然,也持續尋找合作夥伴與資金來源以推動該試驗。
Brian Kemp Dolliver - Analyst
Brian Kemp Dolliver - Analyst
Okay. To be clear, this would be predominantly along the lines of what -- it would be a pharma partner who would take an indication -- this indication may be other indications in order to move the company forward?
好的。為了釐清,這主要會是沿著什麼方向——會是一家藥廠合作夥伴承接某個適應症——這個適應症也可能是其他適應症——以推動公司向前嗎?
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
That's likely the structure of a big pharma deal.
這很可能就是大型藥廠交易的架構。
Brian Kemp Dolliver - Analyst
Brian Kemp Dolliver - Analyst
Thank you.
謝謝。
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Thanks, Kemp.
謝謝你,Kemp。
Operator
Operator
This concludes the question-and-answer session.
問答環節到此結束。
I will now turn the call back over to Dr. Mazzo for closing remarks.
接下來我將把電話會議交回 Mazzo 博士作結語。
David Mazzo - President, Chief Executive Officer, Director
David Mazzo - President, Chief Executive Officer, Director
Again, thank you, all, for participating in today's call.
再次感謝各位參與今天的電話會議。
We remain grateful for your continued interest and support in Lisata.
我們仍然感謝各位持續對 Lisata 的關注與支持。
Stay well. Have a good evening.
祝各位安好。祝各位晚安。
Operator
Operator
Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.
各位女士、先生,今天的電話會議到此結束。感謝各位加入。您現在可以掛線。